natgillin/translations-raw huggingface dataset:
Invanz is used when the bacteria that cause the infection are likely to be killed by the antibiotic.
Zdravilo Invanz se uporabi, če je verjetno, da bo uničilo bakterije, ki povzročajo okužbo.
INVANZ must be reconstituted and then diluted prior to administration.
INVANZ je treba pred infundiranjem pripraviti in nato razredčiti.
INVANZ must be reconstituted and then diluted prior to administration.
Zdravilo INVANZ je treba pred infundiranjem pripraviti in nato razredčiti.
Invanz must not be used in people who are hypersensitive (allergic) to ertapenem or any of the other ingredients, or to other antibiotics of the same group (carbapenems).
Zdravila Invanz ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) ertapenem ali katero koli drugo sestavino zdravila ali druge antibiotike iz iste skupine (karbapenemi).
Invanz was as effective as ceftriaxone or piperacillin/tazobactam for the treatment of abdominal infections, community-acquired pneumonia, gynaecological infections and diabetic foot infections: the same cure rates were reached for both Invanz and the comparator medicine (between 87 and 94% for Invanz, against 83 to 92% for the comparators).
Zdravilo Invanz je bilo enako učinkovito kot ceftriakson ali piperacilin/tazobaktam pri zdravljenju okužb v trebušni votlini, zunajbolnišnične pljučnice, ginekoloških okužb in okužb diabetičnega stopala: zdravilo Invanz in primerjalna zdravila so imeli enake stopnje ozdravitve (med 87 in 94 % za zdravilo Invanz in med 83 in 92 % za primerjalna zdravila).
invasive candidiasis (an infection caused by Candida). ‘Invasive’ means that the infection has spread into the blood; invasive aspergillosis (an infection caused by Aspergillus) when the patient does not respond to or does not tolerate amphotericin B or itraconazole (other antifungal medicines); suspected fungal infections (such as due to Candida or Aspergillus) when the patient is feverish and has low white blood cell counts.
„Invazivna“ pomeni, da se je okužba razširila v kri; invazivno aspergilozo (drugo vrsto glivne okužbe, ki jo povzroča Aspergillus), če se bolnik ne odziva na amfotericin B ali itrakonazol (drugi protiglivni zdravili) ali ju ne prenaša; domnevnimi glivnimi okužbami (npr. zaradi Candide or Aspergillusa), če je bolnik febrilen in mu primanjkuje belih krvničk.
Invasive candidiasis: The treatment duration of Candida infection should be a minimum of 14 days.
Invazivna kandidoza: zdravljenje okužbe z glivami Candida mora trajati najmanj 14 dni.
Invasive fungal infection
invazivna glivna okužba
Invasive intent
Invazivni namen
Invasive pneumococcal disease (which includes sepsis, meningitis, bacteraemic pneumonia and bacteraemia)
2.1. Invazivna pnevmokokna bolezen (ki vključuje sepso, meningitis, bakteriemično pljučnico in bakteriemijo)
INVEGA 1.5 mg prolonged-release tablets
INVEGA 1,5 mg tablete s podaljšanim sproščanjem
INVEGA 1.5 mg prolonged-release tablets INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets
INVEGA 1,5 mg tablete s podaljšanim sproščanjem INVEGA 3 mg tablete s podaljšanim sproščanjem INVEGA 6 mg tablete s podaljšanim sproščanjem INVEGA 9 mg tablete s podaljšanim sproščanjem INVEGA 12 mg tablete s podaljšanim sproščanjem
INVEGA 1.5 mg prolonged-release tablets paliperidone
INVEGA 1,5 mg tablete s podaljšanim sproščanjem paliperidon
INVEGA 12 mg prolonged-release tablets
INVEGA 12 mg tablete s podaljšanim sproščanjem
INVEGA 12 mg prolonged-release tablets paliperidone
INVEGA 12 mg tablete s podaljšanim sproščanjem paliperidon
INVEGA 3 mg prolonged-release tablets
INVEGA 3 mg tablete s podaljšanim sproščanjem
INVEGA 3 mg prolonged-release tablets paliperidone
INVEGA 3 mg tablete s podaljšanim sproščanjem paliperidon
INVEGA 6 mg prolonged-release tablets
INVEGA 6 mg tablete s podaljšanim sproščanjem
INVEGA 6 mg prolonged-release tablets paliperidone
INVEGA 6 mg tablete s podaljšanim sproščanjem paliperidon
INVEGA 9 mg prolonged-release tablets
INVEGA 9 mg tablete s podaljšanim sproščanjem
INVEGA 9 mg prolonged-release tablets paliperidone
INVEGA 9 mg tablete s podaljšanim sproščanjem paliperidon
INVEGA can raise your levels of a hormone called "prolactin" found on a blood test (which may or may not cause symptoms).
Zdravilo INVEGA lahko zviša nivo hormona, ki ga imenujemo "prolaktin" in ga najdemo na krvnih izvidih (ki lahko ali pa ne povzroči simptomov).
INVEGA contains the active substance paliperidone which belongs to the class of antipsychotic medicines.
Zdravilo INVEGA vsebuje zdravilno učinkovino paliperidon, ki sodi v skupino antipsihotičnih zdravil.
INVEGA doses, which varied across the three studies, ranged from 3 to 15 mg once daily.
Odmerki zdravila INVEGA, ki so se razlikovali med temi tremi študijami, so bili v razponu od 3 do 15 mg enkrat na dan.
INVEGA Flexible Dose (3-12 mg)
prilagodljivi odmerek (3-12 mg)
Invega is a medicine that contains the active substance paliperidone.
Invega je zdravilo, ki vsebuje zdravilno učinkovino paliperidon.
INVEGA is for oral administration.
Zdravilo INVEGA je namenjeno peroralni uporabi.
INVEGA is not for use in children and adolescents under 15 years for the treatment of schizophrenia.
Zdravilo INVEGA se ne uporablja za zdravljenje shizofrenije pri otrocih in mladostnikih, mlajših od 15 let.
Invega is used in adults and adolescents from 15 years of age to treat schizophrenia, a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Zdravilo Invega se uporablja pri odraslih in mladostnikih, starejših od 15 let, za zdravljenje shizofrenije, tj. duševne bolezni s številnimi simptomi, kot so nepovezano razmišljanje in govor, halucinacije (prisluhi ali prividi), sumničavost in zmotna prepričanja.
INVEGA is used to treat schizophrenia in adults and in adolescents aged 15 years and older.
Zdravilo INVEGA se uporablja se za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
INVEGA prolonged-release tablets are capsule shaped.
INVEGA tablete s podaljšanim sproščanjem so v obliki kapsule.
Invega was also more effective than placebo in preventing the occurrence of new symptoms of schizophrenia in the long-term study in adults, and the overall results of studies were also considered to support longer-term use in adolescents from 15 years of age.
Zdravilo Invega je bilo prav tako učinkovitejše od placeba pri preprečevanju pojava novih simptomov shizofrenije v dolgoročni študiji pri odraslih,. za skupne rezultate študij pa velja, da podpirajo dolgoročno uporabo zdravila pri mladostnikih, starejših od 15 let.
Invega was more effective than placebo and as effective as olanzapine in reducing the symptoms of schizophrenia in adults.
Zdravilo Invega je bilo pri lajšanju simptomov shizofrenije pri odraslih učinkovitejše od placeba in enako učinkovito kot olanzapin.
INVEGA with alcohol
Zdravilo INVEGA skupaj z alkoholom
Invented
Izmišljeno
Invented
Zaščiteno ime
Invented name
Bovela
Invented name
EU/2/15/191/016
Invented name
Izmišljeno
Invented name
SAT2 Saudi Arabia
Invented name
Taiwan 3/97 in
Invented name
Vsebina
Invented name
zaščiteno ime
Invented name Avaglim
Zaščiteno ime
Invented name Evicel
Izmišljeno
Invented name Pergoveris
Izmišljeno ime
Invented name Prolia
Zaščiteno ime
Invert the bottle
Plastenko obrnite.
Invert the bottle repeatedly following thawing to ensure the contents have resuspended.
Po odtajanju stekleničko večkrat obrnite, da zagotovite, da se vsebina resuspendira.
Invert the pen 10 times.
peresnik 10-krat obrnite.
Invert the solvent vial with the attached transfer device and, gently, insert the green end of the transfer device into the center of the rubber stopper of the upright powder vial (green top).
Obrnite vialo z vehiklom z vstavljenim pripomočkom za prenos, nato pa nežno vstavite zeleni del pripomočka za prenos v središče zamaška pokonci stoječe viale s praškom (zeleni vrh).
Invert the solvent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the product vial stopper.
Obrnite vialo vehikla, na katero je pritrjen komplet Mix2Vial, in porinite konico prozornega adapterja naravnost navzdol skozi zamašek viale z zdravilom.
Invert the solvent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the product vial stopper.
Obrnite vialo vehikla, na katero je pritrjen set Mix2Vial, in porinite konico prozornega adapterja naravnost navzdol skozi zamašek viale z zdravilom.
Investig ations
Preiskav e
Investiga tions
Preiskav e
Investigati ons
Preiskav e
Investigatio ns
oteklina Pireksija10
investigation and analyses of biomarker data into the study protocol of all
podatkov o biomarkerjih v protokol študije pri vseh na novo načrtovanih
Investigational studies have shown that CKD patients not on dialysis treated with cinacalcet have an increased risk for hypocalcaemia (serum
V raziskovalnih študijah se je pokazalo, da je pri bolnikih s kronično boleznijo ledvic, ki se ne zdravijo z dializo, prejemajo pa cinakalcet, tveganje za hipokalciemijo (koncentracije kalcija v serumu <
Investigations
artralgija
Investigations
Laboratorijske preiskave
Investigations
Laboratorijski izvidi
Investigations
navzea
Investigations
Občasni
Investigations
odpoved jeter
Investigations
Organski sistemi po
Investigations
Pogosti:
Investigations
počutjem in zardevanjem)
Investigations
Preiskav e
Investigations
proteinurija
Investigations
reakcije
Investigations
Redki
Investigations
vezivnega tkiva
Investigations
vročinski oblivi/zardevanje
Investigations (Common, ≥1/100 to <1/10)
Preiskave (pogosti, ≥ 1/100 do < 1/10)
Investigations (findings based on test results presented as CTCAE grade shifts)
Preiskave (izsledki na podlagi rezultatov preiskav, prikazani kot premiki stopnje CTCAE)
Investigations Blood creatinine increased
Preiskave zvišanje kreatinina v krvi
Investigations increased body temperature, increased need of catecholamines to support blood pressure (verbatim term: increased need for catecholamines) in the course of the treatment.
Preiskave zvišana telesna temperatura, večja potreba po kateholaminih za vzdrževanje krvnega tlaka (dobeseden izraz: povečana potreba po kateholaminih) tekom zdravljenja.
Investigations increased C-reactive protein
Preiskave zvišanje C reaktivnega proteina
Investigations Not known: electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Preiskave Neznana pogostnost: elektrolitsko neravnovesje (vključno s hipokaliemijo in hiponatriemijo, glejte poglavje 4.4), hiperurikemija, glikozurija, hiperglikemija ter povečanje vrednosti holesterola in trigliceridov
Investigations Very common: Common:
Preiskave zelo pogosti: pogosti:
Investigations*
Preiskave
Investigations: Common: increases in blood urea nitrogen (BUN), creatinine and creatine kinase
Preiskave: Pogosti: zvišanje vrednosti dušika sečnine v krvi (BUN), kreatinina in kreatin-kinaze
Investigations: Not known: electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Preiskave: Neznana: neravnovesje elektrolitov (vključno s hipokaliemijo in hiponatriemijo, glejte poglavje 4.4), hiperurikemija, glikozurija, hiperglikemija in zvišanje vrednosti holesterola ter trigliceridov
Investigationsg
Preiskaveg
Investigator
raziskovalec
Investigator assessed, confirmed ORRs in all treated patients were 25.7% [95% CI: 20.6, 31.4] in the nivolumab group (n=268) vs.
Delež potrjenega objektivnega odziva po oceni raziskovalcev je pri vseh zdravljenih bolnikih v skupini z nivolumabom (n=268) znašal 25,7 % [95 % interval zaupanja: 20,6; 31,4] v primerjavi z
Investigator assessment
Ocena raziskovalcev
Investigator assessment*
Ocena raziskovalca
Investigator radiological review
ocena radiološkega izvida s strani raziskovalca
Investigator's choice therapies included: gemcitabine (intravenous: 22 [41.5%]), fludarabine (intravenous: 12 [22.6%] or oral:
Zdravljenje, ki ga je izbral raziskovalec, je vključevalo: gemcitabin (intravensko: 22 [41,5 %]), fludarabin (intravensko: 12 [22,6 %] ali
Investigator-assessed Duration of response (CR+PR)  (months)
Trajanje odziva po oceni raziskovalca (CR+PR)  (meseci)
Investigator-assessed Myeloma response n (%)
Odziv plazmocitoma po oceni raziskovalca n (%)
Investigator-Assessed PFS
PFS po oceni raziskovalca
Investigator-assessed PFS (PFS-INV)
PFS po raziskovalčevi oceni (PFS-INV)
Investigator-assessed PFS (PFS-INV)a
PFS po raziskovalčevi oceni (PFS-INV)a
Investigator-assessed PFS  (months)
PFS, kot ga je ocenil raziskovalec  (meseci)
Investigator’s Choice (inv choice) n = 54
Po izbiri raziskovalca (INV CHOICE) n = 54
Investigator’s global assessments of efficacy also showed significant improvement.
Preiskovalčevo celostno vrednotenje učinkovitosti je prav tako pokazalo pomembno izboljšanje.
Invirase (hard capsule) 600 mg tid
Invirase (trde kapsule) 600 mg trikrat na dan
Invirase (tablet) 1000 mg bid plus
Invirase (tablete)
Invirase 200 mg hard capsules are light brown and green.
Invirase 200 mg trde kapsule so svetlo rjave in zelene barve.
Invirase 200 mg hard capsules Saquinavir
Invirase 200 mg trde kapsule sakvinavir
INVIRASE 200 mg hard capsules.
INVIRASE 200 mg trde kapsule
INVIRASE 500 mg film-coated tablets.
INVIRASE 500 mg filmsko obložene tablete
Invirase can change how your heart beats – this can be serious.
Zdravilo Invirase lahko spremeni bitje vašega srca - to je lahko resno.
Invirase capsules should be swallowed whole and taken at the same time as ritonavir with or after food (see section 5.2).
Kapsule Invirase je treba pogoltniti cele in jih jemati ob istem času kot ritonavir skupaj s hrano ali po njej (glejte poglavje 5.2).
Invirase comes as a 200 mg capsule or a 500 mg film-coated tablet (see Package Leaflet for Invirase 500 mg film-coated tablets).
Zdravilo Invirase je v obliki 200 mg kapsul ali 500 mg filmsko obloženih tablet (glejte Navodila za uporabo za zdravilo Invirase 500 mg filmsko obložene tablete).
Invirase comes as a 500 mg film-coated tablet or a 200 mg capsule (see Package Leaflet for Invirase 200 mg capsules).
Zdravilo Invirase je v obliki 500 mg filmsko obloženih tablet ali 200 mg kapsulah (glejte Navodila za uporabo za zdravilo Invirase 200 mg kapsule).
Invirase does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Invirase has not been tested for its effect on your ability to drive a car or operate machinery.
Za zdravilo Invirase niso preizkušali vpliva na sposobnost vožnje avtomobila ali upravljanja s stroji.
Invirase is a medicine containing the active substance saquinavir.
Invirase je zdravilo, ki vsebuje zdravilno učinkovino sakvinavir.
Invirase is an antiviral agent.
Zdravilo Invirase je protivirusno zdravilo.
Invirase is available in an amber glass bottle containing 270 capsules.
Zdravilo Invirase je na voljo v steklenički jantarne barve z 270 kapsulami.
Invirase is used to treat adults infected with the human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Invirase se uporablja za zdravljenje odraslih, ki so okuženi z virusom človeške imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Invirase may have a minor influence on the ability to drive and use machines.
Zdravilo Invirase ima lahko blag vpliv na sposobnost vožnje in upravljanja s stroji.
Invirase must be taken together with ritonavir and with or after food.
Zdravilo Invirase je treba zaužiti skupaj z ritonavirjem in hrano ali po njej.
Invirase must not be used in patients who have severe problems with their liver, QT prolongation (an alteration of the electrical activity of the heart), altered levels of electrolytes in the blood (especially low potassium levels), bradycardia (slow heart rate) or heart failure (when the heart does not work as well as it should).
Zdravilo Invirase se ne sme uporabljati pri bolnikih s hudimi ledvičnimi težavami, podaljšanim intervalom QT (spremembo električne dejavnosti v srcu), spremenjenimi ravnmi elektrolitov v krvi (zlasti nizkimi ravnmi kalija), bradikardijo (zelo počasnim srčnim utripom) ali srčnim popuščanjem (kadar srce ne deluje tako, kot bi moralo).
Invirase was assessed in six main studies involving a total of 1,576 patients.
Zdravilo Invirase je bil ocenjeno v šestih glavnih študijah, v katere je bilo vključenih 1 576 bolnikov.
Invirase with food and drink
Zdravilo Invirase skupaj s hrano in pijačo
Invirase, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Invirase v kombinaciji z drugimi protivirusnimi zdravili zmanjša količino virusa HIV v krvi in ga ohranja na nizki ravni.
Invirase, taken in combination with other antiviral medicines, resulted in a reduction of the viral loads and improvements in the immune system.
Jemanje zdravila Invirase v kombinaciji z drugimi protivirusnimi zdravili je povzročilo zmanjšanje virusnega bremena in izboljšanje imunskega sistema.
Invirase/ritonavir (see section 4.3).
poglavje 4.4).
Invirase/ritonavir and other proton
Zaradi možnega pojava življenjsko
Invirase/ritonavir due to potentially
Nefazodon zavira CYP3A4.
Invirase/ritonavir due to potentially
ogrožajoče srčne aritmije so ta
Invirase/ritonavir due to potentially
zdravila Invirase,
Invirase/ritonavir due to the potential
ogrožajoče srčne aritmije je to
Invirase/ritonavir due to the potential
Zaradi možnega pojava življenjsko
Invirase/ritonavir due to the potential
zdravilo kontraindicirano z
Invirase/ritonavir is contraindicated in patients with decompensated hepatic impairment (see sections 4.3 and 4.4).
Pri bolnikih z dekompenzirano boleznijo jeter je uporaba zdravila Invirase/ritonavirja kontraindicirana (glejte poglavji 4.3 in 4.4).
Invirase/ritonavir may be taken with a number of other medications that are commonly used in HIV infection.
Zdravilo Invirase/ritonavir lahko jemljete v kombinaciji s številnimi drugimi zdravili, ki se pogosto uporabljajo pri okužbi s HIV.
Invirase/ritonavir with orally
kot enkratni peroralni
Invirase/ritonavir.
zdravila Invirase,
Invirase/ritonavir.
zdravilom Invirase/ritonavirjem
Invokana 100 mg film-coated tablets (tablets) are yellow, capsule-shaped, 11 mm long, with “CFZ” on one side and “100” on the other side.
Invokana 100 mg filmsko obložene tablete (tablete) so rumene, ovalne, dolge 11 mm, z oznako"CFZ" na eni strani in "100" na drugi strani.
Invokana 100 mg film-coated tablets EU/1/13/884/001 (10 tablets) EU/1/13/884/002 (30 tablets) EU/1/13/884/003 (90 tablets) EU/1/13/884/004 (100 tablets)
Invokana 100 mg filmsko obložene tablete EU/1/13/884/001 (10 tablet) EU/1/13/884/002 (30 tablet) EU/1/13/884/003 (90 tablet) EU/1/13/884/004 (100 tablet)
Invokana 300 mg film-coated tablets (tablets) are white, capsule-shaped, 17 mm long, with “CFZ” on one side and “300” on the other side.
Invokana 300 mg filmsko obložene tablete (tablete) so bele, v ovalne, dolge 17 mm, z oznako"CFZ" na eni strani in "300" na drugi strani.
Invokana 300 mg film-coated tablets EU/1/13/884/005 (10 tablets) EU/1/13/884/006 (30 tablets) EU/1/13/884/007 (90 tablets) EU/1/13/884/008 (100 tablets)
Invokana 300 mg filmsko obložene tablete EU/1/13/884/005 (10 tablet) EU/1/13/884/006 (30 tablet) EU/1/13/884/007 (90 tablet) EU/1/13/884/008 (100 tablet)
Invokana can also be used as an ‘add-on’ to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of the diabetes.
Zdravilo Invokana se lahko uporablja tudi kot dodatek k drugim zdravilom za zdravljenje sladkorne bolezni, vključno z insulinom, kadar ta zdravila skupaj s telesno dejavnostjo in dieto ne zagotavljajo zadostnega nadzora nad sladkorno boleznijo.
Invokana contains lactose
Zdravilo Invokana vsebuje laktozo
Invokana contains the active substance canagliflozin which belongs to a group of medicines called “blood-glucose lowering drugs.”
Zdravilo Invokana vsebuje zdravilno učinkovino kanagliflozin in sodi v skupino zdravil, ki jih imenujemo "zdravila za zniževanje koncentracije glukoze v krvi".
Invokana is not recommended for children and adolescents under 18 years.
Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Invokana ni priporočljiva.
Involuntary eye movement (nystagmus)
nenadzorovano premikanje oči (nistagmus)
involuntary loss of urine (incontinence),
nehotno uhajanje urina (inkontinenca),
involuntary loss of urine (incontinence), difficulty in passing urine
nehotno uhajanje urina (inkontinenca), težave pri odvajanju urina,
Involuntary loss of urine (urinary incontinence), blood in the urine (haematuria), passing more urine than normal (polyuria, pollakiuria), abnormal urine
uhajanje urina (urinska inkontinenca), kri v urinu (hematurija), pogostejše uriniranje od normalnega (poliurija, polakisurija), nenormalni urin
involuntary loss of urine, difficulty in passing urine;
nehotno uhajanje urina, težave pri odvajanju urina;
involuntary movement (dyskinesia),
nehoteno gibanje (diskinezija),
Involuntary muscle contraction (convulsions).
nehotni mišični krči (konvulzije)
involuntary muscle contractions
nehotni mišični krči
Involuntary muscle contractions Abnormal vision
nenadzorovano krčenje mišic motnje vida
Involuntary muscle movements, twitching or spasms
nehotni mišični gibi, trzanje ali spazmi
involuntary muscle spasms (convulsion)
nehoteni mišični krči (konvulzija)
involuntary muscle spasms (convulsion)
nehoteni mišični krči (konvulzija),
involuntary muscle spasms (convulsion)
nehoteni mišični krči (konvulzije)
involuntary shaking movement
nehotno tresenje
Involuntary urination
nenadzorovano uriniranje,
involuntary, irregular muscle movements, especially in the face
nehotne, neredne gibe mišic, zlasti na obrazu,
Involved in Transactional Sex Last 6 Month, N (%)
Sodelovanje v transakcijskem spolnem odnosu v preteklih 6 mesecih, N (%)
IOA 2.5 mg/1.5 mg film-coated tablets
IOA 2,5 mg/1,5 mg filmsko obložene tablete
IOA 2.5 mg/1.5 mg tablets Nomegestrol acetate/estradiol
IOA 2,5 mg/1,5 mg tablete nomegestrolacetat/estradiol
IOA contains lactose
Zdravilo IOA vsebuje laktozo
Ioa is a medicine available as 24 white ‘active’ tablets that contain the active substances nomegestrol acetate (2.5 mg) and estradiol (1.5 mg), and four yellow ‘inactive’ (placebo) tablets that do not contain any active substance.
Zdravilo Ioa je na voljo v obliki 24 belih „aktivnih“ tablet z zdravilnima učinkovinama nomegestrol acetatom (2,5 mg) in estradiolom (1,5 mg) in štirih rumenih „neaktivnih“ (placebo) tablet, ki ne vsebujejo zdravilnih učinkovin.
IOA is not indicated during pregnancy.
Zdravilo IOA ni indicirano za uporabo med nosečnostjo.
IOA is unlikely to affect your ability to drive or use machines.
Malo je verjetno, da bi zdravilo IOA kakor koli vplivalo na vašo sposobnost vožnje in upravljanja strojev.
IOA may also interfere with the working of other medicines – such as the anti-epileptic lamotrigine.
Tudi zdravilo IOA lahko moti delovanje drugih zdravil, npr. antiepileptika lamotrigina.
IOA must not be used by women who are pregnant, or who think they may be pregnant.
Zdravila IOA ne smejo uporabljati ženske, ki so noseče ali menijo, da bi lahko bile noseče.
Ioa nomegestrol acetate / estradiol
Ioa nomegestrol acetat/estradiol
Ioa works by changing the body’s hormonal balance to prevent ovulation, by altering the cervical mucus and by thinning the endometrium (the lining of the womb).
Zdravilo Ioa deluje tako, da spremeni hormonsko ravnovesje telesa in s spremembo sluzi materničnega vratu in tanjšanjem endometrija (maternične sluznice) prepreči ovulacijo.